title: Extracorporeal liver support by recirculating albumin dialysis: analysing the effect of the first clinically used generation of the MARSystem.
abstract: Albumin dialysis with the MARSystem is used in many hospitals to support excretory hepatic function in acute or acute on chronic liver failure. Potential pathogenic albumin bound substances accumulated in excretory liver insufficiency can be removed from patients blood by dialysis against albumin solution. A specific membrane enables the selective transport of albumin bound metabolites to the albumin containing dialysate compartment, where the loaded transport albumin is cleared and regenerated at the same time by adsorption columns and a second dialyser. Between 1993 and 1995 different membranes, set-ups and components in albumin dialysis were tested and led finally to the recirculating MARSystem with a modified polysulphone based membrane (P3/5S Gambro, Hechingen) and two adsorption columns (N350 and BR 350, ASAHI Medical Ltd.), which showed the best performance at this time. This first generation of MARSystems was used clinically between 1995 and 1998 with only minor changes in 15 patients with acute (n = 1) or acute deterioration of chronic liver disease in our department until the improved next generation of MARSystems has been available (MARS set and monitor, Teraklin AG, Rostock, Germany). Changes in blood tests pre/post during 95 single MARS treatments and in clinical status over treatment period were evaluated retrospectively.
  
  
  RESULTS
  A significant decrease of albumin bound substances (average reduction during single MARS treatments: bilirubin -18%, bile acids -43.7%) as well as of water soluble metabolites (creatinine -32%, urea -31%) was observed. During extracorporeal therapy also a significant drop in platelets (- 15.4%) and a prolongation of activated prothrombin time (- 21%) was documented, whereas haemoglobin, WBC, electrolytes as well as transaminases and albumin were not affected significantly.
  
  
  CONCLUSIONS
  Albumin dialysis with the first generation of MARS enables the removal of albumin bound and water soluble toxins. Unwanted side-effects and changes in laboratory tests are comparable to conventional haemodialysis (drop of platelets and prolongation of coagulation tests). The elimination of albumin bound and water soluble substances was accompanied by an improvement of clinical status.
authors.affiliation: University Rostock, Department of Internal Medicine, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Klammt
authors.forename: J
authors.initials: J
authors.lastname: Stange
authors.forename: S R
authors.initials: SR
authors.lastname: Mitzner
authors.forename: P
authors.initials: P
authors.lastname: Peszynski
authors.forename: E
authors.initials: E
authors.lastname: Peters
authors.forename: S
authors.initials: S
authors.lastname: Liebe
mesh_terms: D006519:Hepatitis, Alcoholic / Q000097:blood / Q000628:therapy; D006801:Humans; D017114:Liver Failure, Acute / Q000097:blood / Q000628:therapy*; D006435:Renal Dialysis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000378:metabolism*; D016060:Sorption Detoxification; D016896:Treatment Outcome
chemical_list: D012709:Serum Albumin